Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAvMed Berinert (J0597) Prior Auth Policy Update | …
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Berinert (C1 Esterase Inhibitor) prior authorization for Hereditary Angioedema

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and step-edit requirements for Berinert (J0597) for treatment of acute attacks and prophylaxis of hereditary angioedema (HAE) for AvMed members; applies to prescribers and administrators requesting coverage.

    Policy Summary
    PayerAvMed
    PolicyBerinert (C1 Esterase Inhibitor) prior authorization for Hereditary Angioedema
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit the AvMed Medical Prior Authorization/Step-Edit Request form with required signatures and supporting documentation (lab results, diagnostics, chart notes) to request coverage for Berinert (J0597).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial/reauthorization approval period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=5 yrsMinimum member age for therapy
    160 units/28dExample dosing limit (80 kg)
    J0597HCPCS code for Berinert

    Coverage Criteria for Berinert (C1 Esterase Inhibitor)

    Initial Authorization Criteria

    Covered when ALL of the following are met:

    General conditions: Treatment request is for Hereditary Angioedema (HAE) (e.g., treatment of acute attacks); member is at least 5 years of age; prescribed by or in consultation with a specialist in allergy, immunology, hematology, pulmonology, or medical genetics; provider attests the member is avoiding estrogen-containing oral contraceptives/hormone replacement therapy AND ACE inhibitor therapy; documentation including lab results, diagnostics, and chart notes is provided; initial authorization period: 12 months.

    From checklist items and initial authorization duration

    Attack frequency or severity: Member has a history of ONE of the following clinical presentations: three (3) or more severe HAE attacks per month; moderate to severe cutaneous attacks (without concomitant hives); abdominal attacks (pain and swelling); mild to severe airway swelling attacks (laryngeal/pharyngeal/tongue swelling); disablement for more than 5 days per month by HAE.3+ attacks/month or listed severe presentations

    From member history/clinical presentation bullets

    HAE subtype confirmation: Member has a clinical presentation consistent with an HAE subtype confirmed by repeat blood testing as applicable. HAE I: low C1-INH antigenic level (below lab LLN), low C4, low C1-INH functional level PLUS either family history of HAE or exclusion of acquired angioedema (onset <30 years, normal C1q, no underlying disease such as lymphoma or MGUS). HAE II: normal to elevated C1-INH antigenic level, low C4, low C1-INH functional level PLUS either family history of HAE or exclusion of acquired angioedema. HAE III (normal C1-INH): normal C1-INH antigenic level, normal C4, normal C1-INH functional level AND repeat blood testing during an attack confirming no abnormal labs of HAE I/II AND one of: inadequate response or intolerance to an adequate trial of prophylactic therapy (eg, tranexamic acid or aminocaproic acid, danazol, or progestins), OR known HAE-causing mutation, OR family history with documented lack of efficacy of chronic high-dose antihistamine therapy plus corticosteroids.laboratory values as defined by laboratory lower limit of normal; repeat testing during an attack for HAE III

    Detailed subtype-specific laboratory and history requirements; see checklist for required supporting documentation

    Prior therapy when specified: Member must have trial and failure of icatibant when required (icatibant requires prior authorization) and, for HAE III presentations, inadequate response or intolerance to an adequate trial of listed prophylactic therapies when indicated; submit documentation of prior trials and failures.

    Step-therapy / prior trials requirement and icatibant trial when specified

    Reauthorization

    Reauthorization requirements

    Reauthorization: Member must continue to meet the initial authorization criteria; there must be significant improvement in the severity and duration of attacks that is achieved and sustained; member must not have experienced unacceptable toxicity from the drug (e.g., hypersensitivity reactions).

    Reauthorization period: 12 months; documentation including lab results, diagnostics, and chart notes must be provided

    The use of medication samples to start therapy does not satisfy AvMed's step-edit or prior authorization requirements. Providers should not rely on sample availability as meeting authorization criteria; formal prior authorization with required documentation must be submitted for coverage determination.

    Requests that do not include required laboratory confirmation of the HAE subtype, documentation of specified prior trials (when applicable), or complete supporting records may be delayed or denied. The policy requires subtype-consistent testing (with repeat blood testing as applicable), evidence of trial and failure of indicated prophylactic therapies for certain presentations, and submission of chart notes and lab results to confirm checklist items.

    To avoid denials or delays, include repeat blood testing during an attack when pursuing a diagnosis of HAE III, documentation of trial and failure of icatibant when required, and evidence of inadequate response or intolerance to prophylactic agents (e.g., tranexamic acid, aminocaproic acid, danazol, or progestins) where specified.

    Coding and Dosing Information

    Covered HCPCS/NDCHCPCSCovered
    J0597Berinert, C1 esterase inhibitor (human) (500 unit vial) - HCPCS
    NDC 63833-0825-xxExample NDC for 500 unit vial
    Dosing Limit (Berinert)
    Dosing calculation20 units/kg (example: 80 kg = 1600 units)
    Billing conversion10 units = 1 billable unit
    Example billable limitFor an 80 kg member (1600 units) = 160 billable units per 28 days
    HCPCS / vial sizeJ0597 - 500 unit vial (NDC example: 63833-0825-xx)
    Authorization durationCoverage provided for 12 months, eligible for renewal

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior authorization required — submit AvMed PA/Step-Edit form

    Prior authorization is required for Berinert (J0597) medical benefit; submit the AvMed Medical Prior Authorization/Step-Edit Request form with required signatures and documentation.

    • Drug Requested: Berinert (J0597) (Medical) must be requested via the form
    • Submit with all required supporting documentation to avoid delay
    Step Therapy

    Step therapy — required prior trials for HAE III

    For HAE III with normal C1-INH, the member must have had an inadequate response or intolerance to an adequate trial of prophylactic therapies (e.g., tranexamic acid, aminocaproic acid, danazol, or progestins for females) before approval; trial and failure of icatibant is required when specified elsewhere and documentation must be submitted.

    • Document an inadequate response or intolerance to one listed prophylactic agent for HAE III

    Background

    Hereditary angioedema (HAE) is a disorder characterized by recurrent angioedema attacks. Many cases result from C1 esterase inhibitor (C1‑INH) deficiency or dysfunction (HAE types I and II), while type III presents with normal C1‑INH laboratory values and other genetic causes. Clinical presentations prompting consideration of therapy include frequent or severe attacks (for example, three (3) or more severe attacks per month), cutaneous attacks without hives, abdominal attacks, airway swelling, or disabling symptoms that impair functioning.

    Diagnosis and subtype confirmation depend on laboratory testing: HAE I typically shows low C1‑INH antigenic level, low C4, and low C1‑INH functional level; HAE II shows normal/elevated C1‑INH antigenic level with low C4 and low functional level; HAE III is characterized by normal C1‑INH antigenic level, normal C4, and normal C1‑INH functional level and requires repeat testing during an attack and additional evidence such as a known HAE‑causing mutation or documented inadequate response to prophylactic therapies. Berinert (a plasma‑derived C1 esterase inhibitor) is used for acute attack treatment and for prophylaxis in specified circumstances.

    Definitions and Subtypes

    HAE Subtypes (I, II, III) — Diagnostic Criteria
    HAE Type I diagnostic criteriaLow C1‑INH antigenic level (below lab reference), low C4 level, low C1‑INH functional level, plus either family history of HAE or exclusion of acquired angioedema (onset <30 years, normal C1q, no underlying disease such as lymphoma or MGUS)
    HAE Type II diagnostic criteriaNormal to elevated C1‑INH antigenic level, low C4 level, low C1‑INH functional level, plus either family history of HAE or exclusion of acquired angioedema (onset <30 years, normal C1q, no underlying disease such as lymphoma or MGUS)
    HAE Type III diagnostic criteriaNormal C1‑INH antigenic level, normal C4 level, normal C1‑INH functional level, and repeat blood testing during an attack confirming absence of abnormal labs consistent with HAE I/II; additionally document inadequate response or intolerance to an adequate trial of prophylactic therapies (e.g., tranexamic acid or aminocaproic acid, danazol, or progestins for females) or presence of a known HAE‑causing mutation/family history as applicable
    Policy Summary
    PayerAvMed
    PolicyBerinert (C1 Esterase Inhibitor) prior authorization for Hereditary Angioedema
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit the AvMed Medical Prior Authorization/Step-Edit Request form with required signatures and supporting documentation (lab results, diagnostics, chart notes) to request coverage for Berinert (J0597).
    SourceLink
    On This Page
    Coverage Criteria for Berinert (C1 Esterase Inhibitor)Coding and Dosing InformationProvider Actions and Submission RequirementsBackgroundDefinitions and Subtypes
  1. Icatibant trial and failure is required when indicated (submit prior authorization documentation)
  2. Documentation Required

    Required supporting documentation — labs, diagnostics, chart notes, genetic/family history

    Submit documentation including lab results, diagnostics, and chart notes to support each checklist item; provide HAE subtype confirmation with repeat blood testing as applicable, prior therapy trials/failures (including icatibant when required), and family history or genetic testing evidence when applicable.

    • Laboratory values confirming HAE subtype (C1-INH antigenic level, C4, C1-INH functional level) and repeat testing during an attack for HAE III
    • Chart notes documenting symptoms, frequency/severity of attacks, and prior therapy trials and outcomes
    • Genetic testing or family history documentation for known HAE-causing mutations when applicable
    Documentation Required

    Form completion requirements — signature and required identifiers/data

    The prescriber must sign and clearly print their name on the AvMed PA/Step-Edit Request form; include member identifiers, prescriber identifiers (including NPI), diagnosis and ICD code, dosing, weight and date weight obtained, and contact information to avoid authorization delays.

    • Prescriber signature and printed name (preprinted stamps not valid)
    • Member name and AvMed number, prescriber NPI, office contact, phone and fax
    • Diagnosis and ICD code, drug form/strength, dosing schedule, length of therapy, weight and date weight obtained
    Denial Risk

    Incomplete or illegible submissions may delay or deny authorization

    Authorization can be delayed or denied if the PA form information is incomplete, incorrect, or illegible; incomplete checklist items or missing supporting documentation may lead to denial.

    • Ensure all checklist lines are supported by lab results, diagnostics, and chart notes as requested on the form
    • Use of samples to initiate therapy does not meet step-edit/preauthorization criteria and may affect decision